Treatment of metastatic hormone‑dependent breast cancer with a combination of palbociclib and letrozole – case report

06/2020

MUDr. Věra Benešová

Komplexní onkologické centrum, nemocnice Jihlava

SUMMARY

The antitumor effect of cyclin-dependent kinase 4/6 (CDK4 / 6) inhibitors in combination with hormonal therapy significantly prolongs progression-free survival with prolonged lifespan. The use of this combination therapy in routine clinical practice is fundamentally changing the treatment options of our patients.

Key words

metastatic hormone-dependent breast cancer, palbociclib, letrozole